DR. DANIEL VITT
CEO, President and Director
Dr. Daniel Vitt, Ph.D., joined Immunic in January 2017. Previously, he was Chief Scientific Officer and Chief Development Officer of 4SC AG, a publicly traded company based in Germany that he co-founded in 1997. During his time at 4SC, Dr. Vitt was responsible for all research and development activities and successfully grew the company from the research stage into an advanced therapeutic development company with several clinical-stage product candidates in the pipeline, addressing autoimmune, oncology and infectious diseases. Among these were resminostat, domatinostat and vidofludimus. In 2005, Dr. Vitt took 4SC AG public on the Frankfurt stock exchange.
During his tenure, Dr. Vitt also successfully negotiated and executed several key research and licensing agreements with biotechnology and pharmaceutical companies including Sanofi, LEO Pharma, Yakult Honsha Co., Ltd., Schwarz Pharma and BioNTech AG.
Dr. Vitt studied chemistry in Siegen and Würzburg, Germany, and graduated from the University of Würzburg, where he focused on quantum-chemical calculations of organic reactions. He received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg, where he focused on molecular design of small molecule therapeutics.
Dr. Vitt is currently a member of the supervisory board of Quattro Research GmbH, a software solutions provider for life science and chemistry applications, located in Planegg, Germany.
Entrepreneurial track record and leadership
Co-Founder of 4SC AG, managing director and board member of several companies in the life-science industry
Transformation of R&D company to advanced clinical development stage and IPO on German stock exchange
Leading companies to outstanding levels of excellence
DR. Hella Kohlhof
Chief Scientific Officer
Dr. Hella Kohlhof joined Immunic in January 2017 from 4SC AG, a publicly listed German biotech company where she was responsible for the management of the clinical product portfolio. Dr. Kohlhof also serves as Managing Director of Immunic’s research subsidiary, Immunic Research GmbH, Halle (Saale). She brings to Immunic a very strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology.
In 2008, Dr. Kohlhof joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC’s preclinical and clinical stage projects including IMU-838 and IMU-935. From 2011 to 2015, Dr. Kohlhof was responsible for the management and development of 4SC’s epigenetic clinical stage small molecule inhibitor 4SC-202. In 2015, Dr. Kohlhof was named Director, Development Projects, and assumed responsibility for the entire product development pipeline of 4SC including clinical trial design and biomarker development.
Dr. Kohlhof studied biology in Aachen and Munich, Germany, and Gothenburg, Sweden, and received her doctorate in biology from the Ludwig Maximilians University of Munich. She performed her post doctorate work at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, where she worked on normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling.
Dr. Kohlhof has been awarded several patents and is co-author of several scientific publications. She is a frequent guest speaker at scientific and industry conferences.
Expertise in transitioning from preclinical to clinical-stage development
Experienced in immunology and preclinical research up to managing clinical stage projects
Drug development, preclinical and translational pharmacology, clinical trial design, biomarker development
Developing state-of-the-art treatments of autoimmune diseases
DR. ANDREAS MUEHLER
Chief Medical Officer
Dr. Andreas Muehler, M.D., M.B.A., joined Immunic in August 2016. He has more than 25 years of leadership experience in the U.S. and European pharmaceutical industry, with an emphasis on preclinical and clinical development, business development and licensing, private equity, as well as marketing.
From 2009 until joining Immunic, Dr. Muehler was an independent medical consultant, working on assignments in the U.S. and in Germany. During this time, he served in key interim leadership rolesat a number of pharmaceutical and medical device companies. As such, Dr. Muehler was responsible for overseeing large clinical oncology trials, including the pivotal trials leading up to the launch of newly approved pharmaceuticals for inflammatory bowel disease, Vedolizumab and Budesonide MMX.
In 2009, Dr. Muehler also was a Managing Director of Palladius Healthcare GmbH, a Munich-based healthcare private equity fund. Prior to this, he served at the helm of several U.S. based companies. Specifically, Dr. Muehler was President and Chief Executive Officer of medical device start-up, MicroMRI, Inc. and President of medical device company, 3TP LLC (d/b/a CAD Sciences), which he subsequently sold to iCAD Medical in 2006. Dr. Muehler also served as Chief Executive Officer and Vice President, Corporate Development at Cellectar Inc., a developer of cancer therapeutics and imaging agents. Earlier in his career, Dr. Muehler served in a number of key positions at the mid-sized, U.S.-based pharmaceutical company Berlex Laboratories, where his roles spanned preclinical and clinical development, business development, as well as licensing and marketing.
Dr. Muehler received an M.D. from Humboldt-University in Berlin, Germany, and an M.B.A. from Duke University in Durham, North Carolina. Dr. Muehler has served on the Board of Directors of multiple emerging medical technology companies, is the co-inventor of more than 20 patents and is the author or co-author of more than 70 publications in peer-reviewed journals.
Pharmaceutical industry veteran since 1992
Developed and managed multiple medical companies in the US and Germany
Held multiple interim management positions for pharmaceutical and medical device companies
Developing innovative therapies for patients with debilitating disease
DR. MANFRED GRÖPPEL
Chief Operating Officer
Dr. Manfred Gröppel joined Immunic in April 2016. As part of the senior management team, he has been serving as Chief Operating Officer and, until April 2019, acting Chief Financial Officer leading functional responsibility for accounting, finance, risk management and legal. From April 2016 to December 2016, he served as Immunic’s interim Chief Executive Officer.
Previously, he was Head of Business Development at 4SC AG where he managed worldwide business development activities since 2001 and served as project leader of the development team for IMU-838. Prior to joining 4SC, Dr. Gröppel held various positions at Tripos Inc., where he managed business development activities in Central and South Europe, Scandinavia and Israel. He also worked at the Research Center Siemens from 1994 to 1997.
Dr. Gröppel brings to Immunic more than 18 years of business development leadership and a strong scientific background in drug discovery, product development, manufacturing processes, chemistry, manufacturing and controls (CMC) and project valuation. Dr. Gröppel’s successful track record of licensing transactions in the healthcare industry worldwide totals more than 300 million USD and includes Yakult Honsha’s acquisition of resminostat, Link Health’s acquisition of 4SC-205, out-licensing the APAC rights for resminostat to Menarini, and the acquisition of eight oncology projects from Altana. Recently, he successfully negotiated an option and licensing agreement for Immunic’s IMU-856 with Daiichi Sankyo.
Dr. Gröppel studied chemistry at the University Erlangen-Nuremberg, Germany and received his doctorate in chemistry from the Institute of Organic Chemistry, University Erlangen-Nuremberg.
He has been a guest speaker at several national and international conferences and has been awarded several patents related to IMU-838.
Drug discovery, drug substance & product development, business development, etc.
Doctorate in chemistry
Worldwide business development since 2001
Pushing business development to a new level
TAMARA A. SEYMOUR
Interim Chief Financial Officer
Tamara A. Seymour, M.B.A., joined Immunic in April 2019, bringing with her more than three decades of corporate finance experience in the biotech and life sciences industries.
Since 2018, Ms. Seymour has served as a financial advisor, assisting life sciences companies with merger and acquisition activities and other finance-related needs. From 2014 to 2017, she served as Chief Financial Officer of Signal Genetics Inc. (now miRagen Therapeutics, Inc.), a publicly traded commercial-stage, molecular genetic diagnostics company focused on multiple myeloma. From 2010 to 2014, Ms. Seymour served as Chief Financial Officer of Hemaquest Pharmaceuticals, Inc., a venture-backed clinical development stage biotechnology company developing proprietary small molecules for the treatment of life-threatening hematologic disorders. From 2001 to 2009, Ms. Seymour served as Chief Financial Officer of Favrille, Inc. (now MMR Global, Inc.), a publicly traded clinical development stage biopharmaceutical company developing therapeutic vaccines for non-Hodgkin’s lymphoma. While at Favrille, she was instrumental in raising more than 200 million USD in multiple private and public equity and debt financings, including the company’s IPO. Earlier in her career, Ms. Seymour consulted as Chief Financial Officer for a number of biotechnology companies and served for more than eight years in various positions, including audit manager, with Deloitte LLP and PricewaterhouseCoopers LLP. She is currently a member of the board of directors and audit committee chair of Beacon Discovery, Inc., a privately-held company working to identify and advance molecules targeting G protein-coupled receptors.
Ms. Seymour, a certified public accountant (inactive), received an M.B.A., with an emphasis in finance, from Georgia State University and earned her B.B.A., with an emphasis in accounting, from Valdosta State University.
Expertise in equity and debt financing instruments for private and publicly-traded companies and developing infrastructure necessary for companies to transition from private to publicly-traded
M.B.A. in finance and B.B.A. in accounting, C.P.A. (inactive)
More than 30 years of financial management experience in the life sciences industry
Provide new therapies for patients suffering with debilitating diseases